Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS' PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by ...
Participants were dosed with the study drug, Opdualag, in combination with nivolumab (brand name Opdivo), a different BMS immunotherapy that’s already approved for use in this adjuvant setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback